MedTrace Logo

Preventing Chemotherapy-Induced Peripheral Neuropathy With Acupuncture (PACT Trial)

NCT05528263 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2026-02-24

No results posted yet for this study

Summary

This research is being done to determine whether acupuncture can help prevent or lessen chemotherapy-induced peripheral neuropathy (CIPN), a side effect of some kinds of chemotherapy that causes pain, numbness, tingling, swelling, or muscle weakness mostly in the hands or feet.

This research will also help determine whether acupuncture can improve quality of life in patients receiving taxane-based chemotherapy for the treatment of breast cancer.

The names of the study activities involved in this study are/is:

* Acupuncture treatments for participants in the Acupuncture Group
* Nature videos with a relaxation exercise for participants in the Relaxation/ Exercise Group

The Comprehensive and Integrative Medicine Institute (CIMI) of South Korea is supporting this research study by providing funding.

Conditions

  • Acupuncture
  • Early-stage Breast Cancer
  • Chemotherapy-induced Peripheral Neuropathy
  • Breast Cancer Stage I
  • Breast Cancer Stage II
  • Breast Cancer Stage III

Interventions

DEVICE

Acupuncture

Standardized acupuncture protocol 1-2 times a week for 12 weeks (a total of 14 sessions).

OTHER

Nature scenery with a relaxation exercise

Watch nature scenery videos with a relaxation exercise guide 1-2 times a week for 12 weeks (a total of 14 sessions)

Sponsors & Collaborators

Principal Investigators

  • Weidong Lu, MB, MPH, PhD · Dana-Farber Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-08
Primary Completion
2025-05-30
Completion
2025-05-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05528263 on ClinicalTrials.gov